Welcome to our dedicated page for Schrodinger news (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.
Schrödinger, Inc. (Nasdaq: SDGR) is a computational science company focused on transforming molecular discovery for drug development and materials design. Its news flow reflects activity across software, collaborations, financial performance and a growing therapeutics portfolio, giving investors and industry observers insight into how its physics+AI platform is being applied in practice.
Recent press releases highlight progress in advancing Schrödinger’s physics+AI computational platform, including a predictive toxicology initiative, an AI-powered conversational interface in its Maestro graphical environment, and integration of Lilly’s TuneLab platform into LiveDesign, its cloud-native enterprise informatics environment. These updates illustrate how the company combines physics-based simulations with AI and machine learning to address challenges such as data scarcity in drug discovery.
Schrödinger’s news also covers collaborations and co-founded companies. Examples include expanded research agreements with Ajax Therapeutics, Lilly and Otsuka Pharmaceutical, as well as developments from Nimbus, Structure Therapeutics and Copernic Catalysts, all of which use Schrödinger’s platform in different ways. News items have described positive data for molecules such as zasocitinib, co-invented by Schrödinger and Nimbus, and the creation of a new ammonia synthesis catalyst in collaboration with Copernic.
On the corporate side, SDGR news includes quarterly financial results, updated financial guidance, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Pipeline updates for proprietary programs such as SGR-1505, SGR-3515, SGR-5573 and SGR-6016 appear alongside platform and partnership announcements, providing a combined view of software and drug discovery activities.
Investors and researchers can use the SDGR news page to follow earnings releases, platform enhancements, regulatory designations, collaborative milestones and governance disclosures that shape the company’s trajectory.
Schrödinger (SDGR) has expressed strong support for the FDA's initiative to reduce animal testing requirements in drug development through computational approaches. The company's platform enables accurate in silico predictions for both small molecules and biologics across biological targets.
The company is developing a predictive toxicology solution, funded by the Bill & Melinda Gates Foundation, aimed at improving drug candidate properties and reducing development risks. This initiative focuses on predicting toxicology risks early in drug discovery, particularly regarding off-target protein binding.
Schrödinger has already developed computational models for key off-targets, including recent advances in characterizing safety-related proteins like hERG and cytochrome P450 enzymes. The company plans to launch its predictive toxicology solution in the second half of 2025. Their platform currently includes solutions for predicting protein aggregation in biologics and binding affinity evaluation.
Schrödinger (SDGR) announced upcoming presentations of preclinical data for two investigational cancer treatments at the AACR Annual Meeting 2025 in Chicago. The company will present data on SGR-3515, a Wee1/Myt1 inhibitor, showing improved therapeutic results through optimized intermittent dosing in preclinical oncology models. A Phase 1 clinical trial for SGR-3515 is ongoing, with initial data expected in H2 2025.
Additionally, SDGR will present findings on a machine learning model that predicts drug combination responses with Wee1 inhibitors. The company will also showcase the first preclinical data for SGR-4174, their SOS1 inhibitor targeting KRAS-driven cancers. The data suggests SGR-4174 has a differentiated profile supporting its development for KRAS mutant cancers and rare diseases arising from KRAS pathway mutations.
Schrödinger (SDGR) has announced new inducement grants for recently hired employees. The company granted a non-statutory stock option to purchase 1,575 shares to one employee and restricted stock units (RSUs) for 6,943 shares to seven employees.
The stock option, priced at $22.90 per share, has a ten-year term and vests over four years, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months. The RSUs also vest over four years, with 25% vesting after the first year and the remaining portions vesting annually over three years.
These grants were made under the company's 2021 Inducement Equity Incentive Plan and were approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Schrödinger (Nasdaq: SDGR) has appointed Bridget van Kralingen to its Board of Directors, effective March 7, 2025. Van Kralingen brings over 35 years of experience in global technology and software business leadership. She currently serves as a senior partner at Motive Partners, an investment firm focused on technology-enabled companies.
Prior to her current role, van Kralingen spent nearly 18 years at IBM, most recently as chief executive/senior vice president of IBM Global Markets, where she managed $80 billion in revenue and profit. She previously led IBM's Industry Platforms software division and served as a managing partner at Deloitte Consulting for 15 years.
Van Kralingen currently holds board positions at Teradyne, IEX Group, Travelers Companies, and Discovery
Schrödinger (SDGR) reported strong Q4 and full-year 2024 results, with total software revenue reaching $180.4 million, up 13.3% from 2023. Q4 total revenue increased 19.1% to $88.3 million.
The company's software business showed resilience with total annual contract value increasing 23.7% to $190.8 million. However, full-year drug discovery revenue decreased to $27.2 million from $57.5 million in 2023. The company reported a net loss of $187.1 million for 2024.
Looking ahead to 2025, Schrödinger expects:
- Software revenue growth of 10-15%
- Drug discovery revenue of $45-50 million
- Software gross margin of 74-75%
- Operating expense growth less than 5%
The company expanded collaborations with Eli Lilly and Otsuka, and received a $150 million upfront payment from Novartis in January 2025. Initial Phase 1 data from three proprietary programs is expected in 2025.
Schrödinger (SDGR) has announced its management's participation in three major investor conferences in March 2025. The company will be featured in fireside chat sessions at the following events:
• TD Cowen 45th Annual Health Care Conference on March 4 at 10:30 a.m. ET
• Leerink Partners Global Biopharma Conference on March 10 at 3:40 p.m. ET
• KBCM Healthcare Forum on March 18 at 9:00 a.m. ET
All discussions will be accessible through the Investors section of Schrödinger's website and will remain available for approximately 90 days after each event.
Schrödinger (SDGR) has granted restricted stock units (RSUs) for 5,445 shares of common stock to five newly hired employees on February 17, 2025. The grants were made under the company's 2021 Inducement Equity Incentive Plan and approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs feature a four-year vesting schedule: 25% vests after 12 months of continuous service from the vesting commencement date, followed by the remaining balance vesting in three equal yearly installments of 25% each. These inducement grants are governed by award agreements and the company's 2021 Inducement Equity Incentive Plan.
Schrödinger (Nasdaq: SDGR) has announced it will release its fourth quarter and full-year 2024 financial results on Wednesday, February 26, 2025, after market close. The company will hold a conference call and webcast at 4:30 p.m. ET to discuss the results. Investors can access the live webcast through the company's website's 'Investors' section, where it will remain available for approximately 90 days.
Schrödinger (SDGR) has granted restricted stock units (RSUs) for 4,840 shares of common stock to four newly hired employees on January 20, 2025. The grants were made under the company's 2021 Inducement Equity Incentive Plan and approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs feature a four-year vesting schedule: 25% vests after 12 months of continuous service from the vesting commencement date, followed by the remaining balance vesting in three equal yearly installments of 25% each. These inducement grants are governed by award agreements and the company's 2021 Inducement Equity Incentive Plan.
Schrödinger provided an update on its 2024 progress and outlined its 2025 strategic priorities. Key highlights include:
Expanded Collaborations: Schrödinger expanded its research collaboration with Otsuka Pharmaceutical Co., , and its agreement with Novartis, which includes a $150 million upfront payment expected in Q1 2025.
2024 Achievements: The company launched initiatives to enhance its computational platform and introduced LiveDesign Biologics. It published 29 peer-reviewed articles and advanced Phase 1 clinical studies for SGR-1505, SGR-2921, and SGR-3515. The FDA granted Fast Track Designation to SGR-2921.
Collaborations and Investments: Schrödinger announced a $150 million collaboration with Novartis, with potential milestone payments of up to $2.3 billion. Co-founded companies, including Morphic Holding and Ajax Therapeutics, made significant progress in their respective fields.
2025 Strategic Priorities: Schrödinger aims to increase customer adoption of its technology, advance predictive toxicology, and present initial Phase 1 data for SGR-1505, SGR-2921, and SGR-3515.
Schrödinger will release its Q4 and full-year financial results on February 26, 2025.
FAQ
What is the current stock price of Schrodinger (SDGR)?
What is the market cap of Schrodinger (SDGR)?
